Six months after selling its anti-infective drug Amphotec to Three Rivers Pharmaceuticals LLC, InterMune Inc. has agreed to dispense U.S. and Canadian rights to its hepatitis C compound Infergen to Valeant Pharmaceuticals International Inc. for about $135.5 million in cash. (BioWorld Today)